DeepMVP: deep learning models trained on high-quality data accurately predict PTM sites and variant-induced alterationsBo Wen, Bing Zhang, Chenwei Wang et al.|Nature Methods|2025Cited by 13
Proteogenomic Approaches for the Identification of NF1/Neurofibromin-depleted Estrogen Receptor–positive Breast Cancers for Targeted TreatmentBeom-Jun Kim, Eric C. Chang, Jonathan T. Lei et al.|Cancer Research Communications|2023Cited by 8
Proteogenomic analysis of the CALGB 40601 (Alliance) HER2+ breast cancer neoadjuvant trial reveals resistance biomarkersEric J. Jaehnig, Meenakshi Anurag, Aranzazu Fernandez-Martinez et al.|Cell Reports Medicine|2025Cited by 3
Table S1 from Proteogenomic approaches for the identification of NF1/neurofibromin-depleted estrogen receptor positive breast cancers for targeted treatmentBeom-Jun Kim, Eric C. Chang, Jonathan T. Lei et al.|Unknown|2023Cited by 0
Table S3 from Proteogenomic approaches for the identification of NF1/neurofibromin-depleted estrogen receptor positive breast cancers for targeted treatmentBeom-Jun Kim, Eric C. Chang, Jonathan T. Lei et al.|Unknown|2023Cited by 0